Company Overview

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapies for the treatment of rare diseases, with a primary emphasis on neuromuscular and inflammatory conditions. The company operates within the biotechnology and biopharmaceutical industries and is publicly traded on the Nasdaq under the ticker CAPR. Its core mission is to leverage proprietary cell-derived technologies to address diseases with high unmet medical need.

Capricor’s primary business revolves around the development of CAP-1002, a cardiac-derived cell therapy, and exosome-based therapeutics engineered from its proprietary cell lines. The company’s lead clinical focus is Duchenne muscular dystrophy (DMD), targeting cardiomyopathy and skeletal muscle degeneration associated with the disease. Capricor was founded in 2005 and initially focused on cardiovascular indications before strategically evolving toward rare diseases and regenerative medicine, reflecting both scientific advancements and market opportunity.

Business Operations

Capricor operates through a single reportable segment focused on research and development of biologic therapeutics. Its core assets include CAP-1002, an allogeneic cardiosphere-derived cell therapy, and its exosome platform, which is being developed for both neuromuscular and inflammatory indications. Revenue generation is currently limited, as the company remains in the clinical development stage and does not yet have approved commercial products.

Operations are primarily based in the United States, with research, clinical development, and manufacturing oversight centered at its California facilities. Capricor controls proprietary manufacturing processes and intellectual property related to cell isolation, expansion, and exosome production. The company has engaged in strategic collaborations with academic institutions and patient advocacy organizations to support clinical trials, and it maintains a manufacturing relationship to support clinical-grade biologic production.

Strategic Position & Investments

Capricor’s strategic direction centers on advancing CAP-1002 through late-stage clinical development for DMD cardiomyopathy and expanding its exosome technology platform into additional rare and inflammatory disease indications. The company has received regulatory support mechanisms, including orphan drug designation, which enhances its competitive positioning in rare disease markets.

Investment activity has focused on internal research and development rather than large-scale acquisitions. Capricor has made targeted investments in manufacturing capabilities and intellectual property to support scalable production of biologics. Its exosome program represents an emerging technology area, with potential applications beyond neuromuscular disease, including immunomodulation and fibrosis, though many of these programs remain in preclinical or early clinical stages.

Geographic Footprint

Capricor is headquartered in the United States, with its principal executive offices located in California. The majority of its operational activities, including research, development, and corporate functions, are U.S.-based. Clinical trials, however, involve investigational sites across North America and may extend to other regions as development programs expand.

While Capricor does not currently maintain significant international subsidiaries, its therapies are intended for global markets, particularly in regions with established rare disease regulatory frameworks such as Europe and Asia-Pacific. The company’s international footprint is primarily defined by clinical trial participation and regulatory engagement rather than physical operational presence.

Leadership & Governance

Capricor is led by an executive team with experience in biotechnology, clinical development, and regulatory affairs. The leadership emphasizes a strategy centered on scientific rigor, disciplined capital allocation, and patient-focused development in rare diseases. Corporate governance is overseen by a board of directors with backgrounds in life sciences, finance, and public company leadership.

Key executives include:

• Linda Marbán, Ph.D. – Chief Executive Officer and President
• David C. Weinstein, M.D. – Chief Medical Officer
• Garth Rosenberg – Chief Financial Officer
• Michael D. P. Rosenblatt, Ph.D. – Chief Scientific Advisor

The leadership team’s strategic vision prioritizes advancing late-stage clinical assets, strengthening regulatory positioning, and building long-term value through innovative biologic platforms.